Next 10 |
home / stock / orxof / orxof news
Orexo's patent win for ZUBSOLV® appealed PR Newswire UPPSALA, Sweden , July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
Orexo AB (ORXOY): Q2 GAAP EPS of -SEK2.15.Revenue of SEK142.8M (-20.3% Y/Y)Press Release For further details see: Orexo AB reports Q2 results
Orexo Q4 2020, incl. Full Year Report ZUBSOLV® stable and strong EBIT, despite challenging market due to COVID-19 PR Newswire UPPSALA, Sweden , Jan. 28, 2021 /PRNewswire/ -- Q4 2020 highlights Total net revenues of SEK 159.2 m (238.1 la...
Orexo announces new US patent for ZUBSOLV® PR Newswire UPPSALA, Sweden , Dec. 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®...
Correction notice of press release - Q3 2020 Interim Report - ZUBSOLV® guiding 2020 PR Newswire UPPSALA, Sweden, Nov. 4, 2020 UPPSALA, Sweden , Nov. 4, 2020 /PRNewswire/ -- (STO:ORX) (OTCQX:ORXOY) In connection with the publication of the Interim Rep...
UPPSALA, Sweden and NEW YORK , Sept. 1, 2020 /PRNewswire/ -- Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform, announced the 10 Patient Entrepreneurs selected as finalists for the Lyfebulb and...
UPPSALA, Sweden , Aug. 10, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical Industries Limited ("Sun"). The Notice Letter advises Orexo of Sun's filing of an Abbreviated N...
Orexo AB (publ) ( OTC:ORXOF ) : Q2 GAAP EPS of -SEK0.94. More news on: Orexo AB (publ), Orexo AB (publ), Earnings news and commentary, Healthcare stocks news, Read more ...
UPPSALA, Sweden , July 16, 2020 /PRNewswire/ -- Investing in diversification to drive future growth Q2 2020 highlights Total net revenues of SEK 179.1 m (201.2) EBITDA of SEK -9.0 m (60.4), positive EBITDA of SEK 26.5 m (60.4) excluding accelerated DTx US launch ...
FDA's "Enforcement Policy" and Orexo's strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies Preliminary estimated sales potential of USD 420 -650 million for the DTx portfolio five years post launch To enab...
News, Short Squeeze, Breakout and More Instantly...
Orexo Ab Ord Company Name:
ORXOF Stock Symbol:
OTCMKTS Market:
Orexo's patent win for ZUBSOLV® appealed PR Newswire UPPSALA, Sweden , July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...
Orexo Q4 2020, incl. Full Year Report ZUBSOLV® stable and strong EBIT, despite challenging market due to COVID-19 PR Newswire UPPSALA, Sweden , Jan. 28, 2021 /PRNewswire/ -- Q4 2020 highlights Total net revenues of SEK 159.2 m (238.1 la...
Orexo announces new US patent for ZUBSOLV® PR Newswire UPPSALA, Sweden , Dec. 30, 2020 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®...